Naoki Furuya

St. Marianna University School Of Medicine
Kawasaki, 2168511, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 106 publications

Surgical Complexity and Perioperative Feasibility Following Neoadjuvant Chemotherapy, Chemoradiotherapy, or Chemoimmunotherapy in Stage II-III Non-Small Cell Lung Cancer: A Retrospective Single-Institution Study.

Surgical Complexity and Perioperative Feasibility Following Neoadjuvant Chemotherapy, Chemoradiotherapy, or Chemoimmunotherapy in Stage II-III Non-Small Cell Lung Cancer: A Retrospective Single-Institution Study.

Journal: Cancers

Published: August 03, 2026

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 29, 2026

Beyond rash management with amivantamab-lazertinib for EGFR-mutated non-small cell lung cancer: the unresolved challenge of paronychia in the COCOON trial.

Beyond rash management with amivantamab-lazertinib for EGFR-mutated non-small cell lung cancer: the unresolved challenge of paronychia in the COCOON trial.

Journal: Journal of thoracic disease

Published: March 14, 2026

Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.

Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.

Journal: Anticancer research

Published: February 28, 2026

Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression.

Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 03, 2026

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 03, 2026

EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics.

EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics.

Journal: Future oncology (London, England)

Published: August 22, 2025

Immune checkpoint inhibitors for advanced non-small cell lung cancer with poor performance status or older patients.

Immune checkpoint inhibitors for advanced non-small cell lung cancer with poor performance status or older patients.

Journal: Journal of thoracic disease

Published: July 21, 2025

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1.

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 17, 2025

Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression.

Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression.

Journal: Anticancer research

Published: July 08, 2025

Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.

Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.

Journal: International journal of clinical oncology

Published: May 05, 2025

Showing 1-12 of 106

Last Updated: 09/26/2026